文献速递放疗物理与技术姑息放疗与转移瘤

距质子治疗中心较远与多中心放射肿瘤登记患者随访能力下降相关

Increased distance from a treating proton center is associated with diminished ability to follow patients enrolled on a multicenter radiation oncology registry.
PubMed 文献 · Radiother Oncol · 2019-01-31

研究分析MGH儿童质子联盟登记(PPCR)中333例接受质子治疗的患者,评估影响最长随访时间的因素。中位随访2.4年,中位距离256.4公里;距中心超过121公里的患者平均随访时间少0.53年(p=0.0002),Medicaid保险、因保险延迟治疗及非白人种族也与随访损失相关,共同参与质子试验或在机构就诊者随访增加近一年(p<0.0001)。

要点

  • 距质子中心超过121公里的患者平均随访时间少0.53年(p=0.0002)。
  • Medicaid保险、因保险延迟治疗及非白人种族与随访损失相关。
  • 共同参与质子试验或在机构就诊者随访增加近一年(p<0.0001)。

核心结论

  • 居住地距治疗质子中心较远的患者随访时间较短,可能对临床结局研究产生不利影响。

研究设计与样本

  • 基于MGH儿童质子联盟登记(PPCR)的回顾性分析,纳入2012年10月至2017年3月入组的333例接受质子治疗的患者,排除因死亡或退出研究而终止者,采用单变量和多变量分析确定与随访时间相关的风险因素。

主要发现

  • 中位随访时间为2.4年(<1-5.5),距质子中心中位距离为256.4公里(<1.6-16,949.6)。
  • 居住在波士顿大都会统计区以外、距质子中心超过121公里的患者,平均随访时间比121公里以内者少0.53年(p=0.0002)。
  • Medicaid保险、因保险延迟治疗及非白人种族也与平均随访时间损失相关。
  • 共同参与质子试验或在机构就诊的患者随访时间显著增加近一年(p<0.0001)。

临床怎么用

  • 对距质子中心较远、Medicaid保险、因保险延迟治疗及非白人种族的患者,应加强随访管理以减少失访。
  • 加强医疗服务提供者之间的医疗信息共享并改进收集方法,以有效评估质子治疗的获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Consistent follow-up and data collection are necessary to identify long-term benefits/detriments of proton radiotherapy. Obtaining comprehensive clinical follow-up can be difficult and time-intensive for proton centers. Here we evaluate what factors affect maximum follow-up time among MGH Pediatric Proton Consortium Registry (PPCR) participants. PATIENTS AND METHODS: Enrollment in the PPCR was offered to any patient <22 years receiving protons. Patients were excluded from analysis if they were taken off study due to death or withdrawal. Distance from MGH was calculated by the great-circle formula. We utilized both univariate and multivariate analyses to determine risk factors associated with follow-up time. RESULTS: 333 PPCR patients enrolled between 10/2012 and 03/2017 were included. Median follow-up was 2.4 years (<1-5.5), and median distance away from the proton center was 256.4 km (<1.6-16,949.6). Distance from MGH significantly predicted follow-up time: patients living outside the Boston Metropolitan Statistical Area, >121 km from the proton center, had average follow-up that was 0.53 years less compared to those living within 121 km (p = 0.0002). Loss in average follow-up was also associated with Medicaid insurance, treatment delay due to insurance, and non-White race. Those co-enrolled on a proton trial or seen at a facility had significantly increased follow-up by almost one year (p < 0.0001). CONCLUSION: Patients living further from treating proton center have shorter follow-up durations. Increased distance from treating centers may adversely affect clinical outcomes research. Enhanced sharing of medical information among care providers and improved collection methods are needed to effectively evaluate the benefits of proton therapy.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Lawell MP, Bajaj BVM, Gallotto SL, et al. Increased distance from a treating proton center is associated with diminished ability to follow patients enrolled on a multicenter radiation oncology registry. Radiother Oncol. 2019. PMID: 31005220. doi:10.1016/j.radonc.2019.01.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。